As a promising TGF-β2 inhibitor, specific oligodeoxynucleotides (ODNs) targeting TGF-β2 have also been developed to directly treat some types of cancer, such as high recurrence of malignant glioma, pancreatic cancer, melanoma, and triple-negative breast cancer (17–20). Here, TGFB2 is linked to cancer.